COVID shot drives CanSinoBIO's first six-month profit since at least 2019

1 minute read

A logo of China's vaccine specialist CanSino Biologics Inc is pictured on the company's headquarters in Tianjin, following an outbreak of the coronavirus disease (COVID-19), China August 17, 2020. REUTERS/Thomas Peter/File Photo

Register now for FREE unlimited access to Reuters.com

BEIJING, Aug 27 (Reuters) - Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) (6185.HK) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of its COVID-19 shot.

That compared with 123.0 million yuan of operating loss in the same period a year ago, CanSinoBIO said in a filing in the Hong Kong stock exchange.

It marks the first six-month profit since at least 2019. The firm is yet to achieve full-year profits since it went public in 2018 in Hong Kong.

Register now for FREE unlimited access to Reuters.com

It reported 937.1 million yuan profit and total comprehensive income for the first six months of 2021.

Its single-dose COVID-19 shot, named Ad5-nCoV, has been approved for use in countries including China, Mexico, Pakistan and Chile.

The vaccine approvals were one of the major drivers for the sixth-month profit, CanSinoBIO said.

($1 = 6.4813 Chinese yuan renminbi)

Register now for FREE unlimited access to Reuters.com
Reporting by Roxanne Liu and Ryan Woo; Editing by Catherine Evans

Our Standards: The Thomson Reuters Trust Principles.